Brian Skorney
Stock Analyst at Baird
(4.29)
# 491
Out of 4,425 analysts
61
Total ratings
50%
Success rate
17.29%
Average return
Main Sectors:
22 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Initiates: Outperform | $72 | $44.99 | +60.04% | 1 | May 10, 2024 | |
| MRNS Marinus Pharmaceuticals | Downgrades: Neutral | $20 → $2 | $1.33 | +50.38% | 4 | Apr 16, 2024 | |
| RGNX REGENXBIO | Maintains: Outperform | $34 → $39 | $15.44 | +152.59% | 3 | Mar 6, 2024 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $45 → $52 | $48.00 | +8.33% | 3 | Feb 29, 2024 | |
| ANRO Alto Neuroscience | Initiates: Outperform | $32 | $13.49 | +137.21% | 1 | Feb 27, 2024 | |
| BIIB Biogen | Maintains: Outperform | $333 → $316 | $221.50 | +42.66% | 6 | Feb 14, 2024 | |
| BHVN Biohaven Pharmaceutical Holding Company | Initiates: Outperform | $58 | $35.69 | +62.51% | 1 | Dec 8, 2023 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $63 | $40.54 | +55.40% | 1 | Dec 8, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $140 → $148 | $136.70 | +8.27% | 3 | Aug 2, 2023 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $760 | $973.80 | -21.96% | 8 | Jun 28, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $280 → $325 | $422.78 | -23.13% | 14 | May 2, 2023 | |
| APLT Applied Therapeutics | Maintains: Outperform | $18 → $14 | $4.39 | +218.91% | 2 | Apr 25, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $152 → $202 | $131.82 | +53.24% | 2 | Mar 1, 2023 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $130 → $90 | $12.65 | +611.46% | 3 | May 19, 2022 | |
| RPHM Reneo Pharmaceuticals | Initiates: Outperform | $28 | $1.81 | +1,446.96% | 1 | Jan 27, 2022 | |
| IMVT Immunovant | Downgrades: Neutral | n/a | $29.39 | - | 1 | Aug 3, 2021 | |
| VTGN VistaGen Therapeutics | Initiates: Outperform | n/a | $4.37 | - | 1 | May 20, 2021 | |
| VYGR Voyager Therapeutics | Downgrades: Neutral | n/a | $8.44 | - | 1 | Feb 26, 2021 | |
| MIRM Mirum Pharmaceuticals | Initiates: Outperform | n/a | $24.76 | - | 1 | Jun 25, 2020 | |
| AMGN Amgen | Downgrades: Underperform | n/a | $310.15 | - | 2 | Jan 31, 2020 | |
| CRIS Curis | Maintains: Outperform | n/a | $15.72 | - | 1 | May 7, 2018 | |
| BGNE BeiGene | Downgrades: Neutral | n/a | $161.13 | - | 1 | Nov 14, 2017 |
Soleno Therapeutics
May 10, 2024
Initiates: Outperform
Price Target: $72
Current: $44.99
Upside: +60.04%
Marinus Pharmaceuticals
Apr 16, 2024
Downgrades: Neutral
Price Target: $20 → $2
Current: $1.33
Upside: +50.38%
REGENXBIO
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $15.44
Upside: +152.59%
Crinetics Pharmaceuticals
Feb 29, 2024
Maintains: Outperform
Price Target: $45 → $52
Current: $48.00
Upside: +8.33%
Alto Neuroscience
Feb 27, 2024
Initiates: Outperform
Price Target: $32
Current: $13.49
Upside: +137.21%
Biogen
Feb 14, 2024
Maintains: Outperform
Price Target: $333 → $316
Current: $221.50
Upside: +42.66%
Biohaven Pharmaceutical Holding Company
Dec 8, 2023
Initiates: Outperform
Price Target: $58
Current: $35.69
Upside: +62.51%
Xenon Pharmaceuticals
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $40.54
Upside: +55.40%
Neurocrine Biosciences
Aug 2, 2023
Maintains: Outperform
Price Target: $140 → $148
Current: $136.70
Upside: +8.27%
Regeneron Pharmaceuticals
Jun 28, 2023
Maintains: Neutral
Price Target: $800 → $760
Current: $973.80
Upside: -21.96%
Vertex Pharmaceuticals
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $422.78
Upside: -23.13%
Applied Therapeutics
Apr 25, 2023
Maintains: Outperform
Price Target: $18 → $14
Current: $4.39
Upside: +218.91%
Sarepta Therapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $152 → $202
Current: $131.82
Upside: +53.24%
Enanta Pharmaceuticals
May 19, 2022
Maintains: Outperform
Price Target: $130 → $90
Current: $12.65
Upside: +611.46%
Reneo Pharmaceuticals
Jan 27, 2022
Initiates: Outperform
Price Target: $28
Current: $1.81
Upside: +1,446.96%
Immunovant
Aug 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $29.39
Upside: -
VistaGen Therapeutics
May 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.37
Upside: -
Voyager Therapeutics
Feb 26, 2021
Downgrades: Neutral
Price Target: n/a
Current: $8.44
Upside: -
Mirum Pharmaceuticals
Jun 25, 2020
Initiates: Outperform
Price Target: n/a
Current: $24.76
Upside: -
Amgen
Jan 31, 2020
Downgrades: Underperform
Price Target: n/a
Current: $310.15
Upside: -
Curis
May 7, 2018
Maintains: Outperform
Price Target: n/a
Current: $15.72
Upside: -
BeiGene
Nov 14, 2017
Downgrades: Neutral
Price Target: n/a
Current: $161.13
Upside: -